The much anticipated SIRFLOX study has failed to demonstrate a statistically significant increase in progression free survival (PFS; measures the time interval...

The much anticipated SIRFLOX study has failed to demonstrate a statistically significant increase in progression free survival (PFS; measures the time interval from trail start to the time when the cancer starts to regrow) for main product SIR-Spheres microspheres combined with chemotherapy compared to chemotherapy alone in secondary liver cancer patients. While the trial did show the product increased PFS in the liver in a statistically significant manner, this is a secondary endpoint of the study which did not translate into any patient benefit. The full trial details to be presented at the American Society of Clinical Oncology (ASCO) meeting held 29 May- 2 June 2015. While we do not expect unfavourable results to negatively impact uptake of the device in its current 'salvage setting', trading levels have optimistically baked-in favourable trial results, with downside of 48-62% as we view fair value in the $15-20 range. Sirtex (SRX, Reduce, Price Target A$15.63) (Source:Derek jellinek) @morgans